Astrazeneca (AZN) Other Operating Expenses (2009 - 2026)

Astrazeneca has reported Other Operating Expenses for 18 years, with the latest figure at $152.0 million in Q2 2026.

• On a quarterly basis, Other Operating Expenses rose 92.41% year-over-year to $152.0 million in Q2 2026; TTM through Jun 2026 was $824.0 million, a 159.94% increase from a year earlier, with the FY2025 full-year figure at $381.0 million, up 51.19% from the prior year.
• Other Operating Expenses was $152.0 million for Q2 2026 at Astrazeneca, down from $189.0 million in the prior quarter.
• The five-year high for Other Operating Expenses was $1.2 billion in Q4 2023, with the low at $25.0 million in Q3 2024.
• Average Other Operating Expenses over 5 years is $236.0 million, with a median of $109.5 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Other Operating Expenses jumped 552.38% in 2023, then tumbled 92.35% in 2024.
• Over 5 years, Other Operating Expenses stood at $189.0 million in 2022, then surged by 552.38% to $1.2 billion in 2023, then slumped by 91.89% to $100.0 million in 2024, then soared by 294.0% to $394.0 million in 2025, then slumped by 61.42% to $152.0 million in 2026.
• The last three Other Operating Expenses figures came in at $152.0 million (Q2 2026), $189.0 million (Q1 2026), and $394.0 million (Q4 2025), per Business Quant data.